Special Issue "Epigenetic Drugs"
Deadline for manuscript submissions: 15 December 2021.
Many diseases (e.g., cancer, diabetes, heart, mental, and autoimmune diseases) are associated with epigenetic aberrations including DNA methylation, histone post-translational modifications, chromatin remodeling, and regulatory RNA. Until now, the DNMT inhibitors 5-azacytidine and 5-aza-20-deoxycytidine and the HDAC inhibitors belinostat, panobinostat, romidepsin, vorinostat have been approved by the FDA for the treatment of various cancers. Many of these drugs suffer from high toxicity, rapid metabolism, poor bioavailability, and limited effectiveness in monotherapy. However, in combinatorial therapy, they can be beneficial to patients. In this Special Issue, we would like to invite the submission of manuscripts containing new findings, which may contribute to the design and use of new epigenetic drugs with improved activity, functional significance of different epigenetic drugs (or candidates)-induced signaling pathways and their clinical implications, improvement of the new drugs selectivity, identification of new molecular targets of epigenetic drugs and their clinical significance, and potential combined epigenetic therapies.
We look forward to your contributions.
Dr. Marcin Ratajewski
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- epigenetic modulating agents
- epigenetic drug discovery
- DNA methylation
- histone post-translational modifications
- chromatin remodeling
- epigenetic markers
- cancer epigenetics
- epigenetic therapeutics in immunotherapy
- combined therapy